Skip to content

Prevention of Seasonal Affective Disorder

A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00046241
Enrollment
300
Registered
2002-09-25
Start date
2002-09-30
Completion date
2003-06-30
Last updated
2017-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal Affective Disorder

Keywords

seasonal depression winter blues winter depression

Brief summary

This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).

Interventions

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion criteria

* Patient has a current or past history of seizure disorder or brain injury. * Patient has a history or current diagnosis of anorexia nervosa or bulimia. * Patient has recurrent summer depression more frequently than winter depression. * Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders. * Patient has initiated psychotherapy within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Time between randomization and onset of a seasonal depressive episode. Proportion of depression-free subjects.

Secondary

MeasureTime frame
Change in HAMD-24 and -17 total score. Change in pain score.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026